Diagnosis and prognosis of traumatic pulmonary psuedocysts : a review of 12 casesCHON, Soon-Ho; CHUL BURM LEE; KIM, Hyuck et al.European journal of cardio-thoracic surgery. 2006, Vol 29, Num 5, pp 819-823, issn 1010-7940, 5 p.Article

Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutationYOUNG HAK KIM; NISHIMURA, Takashi; OZASA, Hiroaki et al.Chemotherapy (Basel). 2013, Vol 59, Num 6, pp 414-419, issn 0009-3157, 6 p.Article

Performance Status and Sensitivity to First-line Chemotherapy Are Significant Prognostic Factors in Patients With Recurrent Small Cell Lung Cancer Receiving Second-line ChemotherapyYOUNG HAK KIM; GOTO, Koichi; YOH, Kiyotaka et al.Cancer. 2008, Vol 113, Num 9, pp 2518-2523, issn 0008-543X, 6 p.Article

Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancerYOUNG HAK KIM; YOH, Kiyotaka; NIHO, Seiji et al.Respiratory medicine. 2010, Vol 104, Num 3, pp 434-439, issn 0954-6111, 6 p.Article

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literatureTOGASHI, Yosuke; MASAGO, Katsuhiro; HAMATANI, Yasuhiro et al.Lung cancer. 2012, Vol 77, Num 2, pp 464-468, issn 0169-5002, 5 p.Article

Predictive factors for local recurrence of resected colorectal lung metastasesSHIONO, Satoshi; ISHII, Genichiro; IWASAKI, Motoki et al.The Annals of thoracic surgery. 2005, Vol 80, Num 3, pp 1040-1045, issn 0003-4975, 6 p.Article

Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung CancerFUKUDO, Masahide; IKEMI, Yasuaki; KATSURA, Toshiya et al.Clinical pharmacokinetics. 2013, Vol 52, Num 7, pp 593-609, issn 0312-5963, 17 p.Article

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancerTOGASHI, Yosuke; MASAGO, Katsuhiro; FUJITA, Shiro et al.Lung cancer. 2011, Vol 74, Num 1, pp 98-102, issn 0169-5002, 5 p.Article

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutationTOGASHI, Yosuke; MASAGO, Katsuhiro; MISHIMA, Michiaki et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 4, pp 1089-1092, issn 0344-5704, 4 p.Article

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902YOUNG HAK KIM; HIRABAYASHI, Masataka; TOMIOKA, Hiromi et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 2, pp 271-276, issn 0344-5704, 6 p.Article

Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung AdenocarcinomaTOGASHI, Yosuke; MASAGO, Katsuhiro; KUBO, Takeshi et al.Cancer. 2011, Vol 117, Num 4, pp 819-825, issn 0008-543X, 7 p.Article

Re-challenge chemotherapy for relapsed non-small-cell lung cancerNAGANO, Tatsuya; YOUNG HAK KIM; GOTO, Koichi et al.Lung cancer. 2010, Vol 69, Num 3, pp 315-318, issn 0169-5002, 4 p.Article

Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received GefitinibMASAGO, Katsuhiro; FUJITA, Shiro; MIO, Tadashi et al.Oncology. 2010, Vol 79, Num 5-6, pp 355-362, issn 0030-2414, 8 p.Article

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancerYOUNG HAK KIM; ISHII, Genichiro; GOTO, Koichi et al.Lung cancer. 2009, Vol 65, Num 1, pp 105-111, issn 0169-5002, 7 p.Article

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyOTA, Shuji; ISHII, Genichiro; OCHIAI, Atsushi et al.Lung cancer. 2009, Vol 64, Num 1, pp 98-104, issn 0169-5002, 7 p.Article

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerTOGASHI, Yosuke; MASAGO, Katsuhiro; MISHIMA, Michiaki et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 3, pp 399-405, issn 0344-5704, 7 p.Article

Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancerMASAGO, Katsuhiro; FUJITA, Shiro; MISHIMA, Michiaki et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 2, pp 325-330, issn 0344-5704, 6 p.Article

Association of the transforming growth factor ss1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancerTOGASHI, Yosuke; MASAGO, Katsuhiro; FUJITA, Shiro et al.Oncology reports. 2011, Vol 25, Num 2, pp 377-382, issn 1021-335X, 6 p.Article

Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancerMASAGO, Katsuhiro; FUJITA, Shiro; MISHIMA, Michiaki et al.Oncology reports. 2011, Vol 26, Num 4, pp 795-803, issn 1021-335X, 9 p.Article

Dominant papillary subtype is a significant predictor of the response to Gefitinib in adenocarcinoma of the lungYOUNG HAK KIM; ISHII, Genichiro; GOTO, Koichi et al.Clinical cancer research. 2004, Vol 10, Num 21, pp 7311-7317, issn 1078-0432, 7 p.Article

Druggable Oncogene Fusions in Invasive Mucinous Lung AdenocarcinomaNAKAOKU, Takashi; TSUTA, Koji; NOKIHARA, Hiroshi et al.Clinical cancer research (Print). 2014, Vol 20, Num 12, pp 3087-3093, issn 1078-0432, 7 p.Article